Lupin launches generic Moxeza
Patients with bacterial conjunctivitis have a new generic treatment option available. Lupin is introducing moxifloxacin ophthalmic solution in a dosage strength of 0.5%, having received the Food and Drug Administration’s blessing earlier.
The product is the generic of Novartis’ Moxeza.
Moxifloxacin ophthalmic solution had a market value of approximately $10 million, according to IQVIA December 2019 data.
The product will be manufactured in Lupin’s Pithampur (Unit-II) facility, in India.